Insulin Glargine Market Will Predicted at 4.0% CAGR to Reach 7780 Million US$ by the End of 2025
Insulin glargine, marketed under the names Lantus among others, is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours, with a "peakless" profile (according to the insulin glargine package insert).
View full press release